**MEDTECS INTERNATIONAL CORPORATION LIMITED**

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

**Unaudited Half Year Financial Statements For The Period Ended 30 June (“1H”) 2026**

**CONDENSED INTERIM STATEMENTS OF INCOME**

| | Group | | |
|---|---|---|---|
| | US$'000 | | % |
| | Latest Half Year Ended 30 June 2026 | Previous Half Year Ended 30 June 2025 | Increase/ (Decrease) |
| **Revenue** | 42,315 | 36,438 | 16.1 |
| Costs of sales and services | (35,112) | (28,954) | 21.3 |
| **Gross profit** | 7,203 | 7,484 | (3.8) |
| **Other items of income** | | | |
| Other operating income, net | 1,781 | 108 | N.M. |
| Financial income | 249 | 632 | (60.6) |
| **Other items of expense** | | | |
| Distribution and selling expenses | (2,739) | (2,891) | (5.3) |
| Administrative expenses | (5,684) | (4,753) | 19.6 |
| Financial expenses | (335) | (337) | (0.6) |
| **Profit before tax** | 475 | 243 | 95.5 |
| Income tax expense | (10) | (63) | (84.1) |
| **Net profit for the period** | 465 | 180 | 158.3 |
| **Attributable to:** | | | |
| Equity holders of the Company | 463 | 178 | 160.1 |
| Non-controlling interests | 2 | 2 | - |
| **Net profit for the period** | 465 | 180 | 158.3 |

| | US$'000 | |
|---|---|---|
| | Latest Half Year Ended 30 June 2026 | Previous Half Year Ended 30 June 2025 |
| Depreciation | 1,688 | 1,766 |
| Amortisation of: | | |
| Assets held for leasing | 973 | 977 |
| Right-of-use assets | 413 | 365 |
| Intangible assets | 125 | 125 |
| Interest expense on: | | |
| Loans | 204 | 211 |
| Lease liabilities | 108 | 97 |
| Provision for expected credit losses on non-trade receivables | 1,000 | – |
| Reversal of write-down of inventory | (297) | (1,440) |
| Other finance cost | 23 | 29 |
| Gain on deconsolidation of subsidiary | (1,045) | – |
| Interest income | (249) | (632) |
| Foreign exchange losses | 40 | 465 |

**N.M.: Not meaningful**

**CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE INCOME**

| | Group | | |
|---|---|---|---|
| | US$'000 | | % |
| | Latest Half Year Ended 30 June 2026 | Previous Half Year Ended 30 June 2025 | Increase/ (Decrease) |
| Net profit after tax | 465 | 180 | 158.3 |
| Other comprehensive income: | | | |
| *Item that may be reclassified subsequently to profit or loss* | | | |
| Exchange difference on consolidation | (10) | 459 | (102.2) |
| Actuarial losses | – | (106) | (100.0) |
| Total comprehensive income | 455 | 533 | (14.6) |
| **Attributable to:** | | | |
| Equity holders of the Company | 453 | 531 | (14.7) |
| Non-controlling interests | 2 | 2 | – |
| Total comprehensive income | 455 | 533 | (14.6) |

**CONDENSED INTERIM BALANCE SHEETS**

| | | Group US$'000 | | Company US$'000 | |
|---|---|---|---|---|---|
| | | 30 June 2026 | 31 Dec 2025 | 30 June 2026 | 31 Dec 2025 |
| **ASSETS** | | | | | |
| **Non-current assets** | | | | | |
| Property, plant and equipment, net | Note 1 | 16,261 | 51,612 | 13 | 21 |
| Investment properties | | 2,228 | 2,283 | – | – |
| Assets held for leasing | | 3,516 | 3,751 | – | – |
| Right-of-use of assets | | 10,291 | 9,723 | 188 | 248 |
| Net investment in sub-lease | | – | – | 3,874 | 4,271 |
| Investment in subsidiaries | | – | – | 50,749 | 50,749 |
| Intangible assets | | 2,828 | 2,839 | – | – |
| Non-trade receivables | Note 2 | 19,690 | – | – | – |
| Deferred tax assets | | 1,581 | 1,581 | – | – |
| Other non-current assets | | 1,267 | 1,358 | 108 | 108 |
| | | 57,662 | 73,147 | 54,932 | 55,397 |
| **Current assets** | | | | | |
| Inventories | Note 3 | 23,737 | 28,215 | 356 | 603 |
| Trade receivables | Note 4 | 14,012 | 19,252 | 123 | 117 |
| Other current assets | | 5,170 | 5,761 | 283 | 242 |
| Non-trade receivables | Note 2 | 6,900 | – | – | – |
| Fixed deposits | Note 5 | 10,319 | 3,865 | 47 | 47 |
| Cash and bank balances | Note 5 | 12,450 | 15,503 | 1,714 | 1,397 |
| | | 72,588 | 72,596 | 2,523 | 2,406 |
| **TOTAL ASSETS** | | 130,250 | 145,743 | 57,455 | 57,803 |

| EQUITY AND LIABILITIES | | Group US$'000 | | Company US$'000 | |
|---|---|---|---|---|---|
| | | 30 June 2026 | 31 Dec 2025 | 30 June 2026 | 31 Dec 2025 |
| **Current liabilities** | | | | | |
| Accounts payable and other current liabilities | Note 6 | 5,048 | 20,571 | 660 | 700 |
| Lease liabilities | | 819 | 819 | 148 | 148 |
| Due to subsidiaries (trade) | | – | – | 18,594 | 19,589 |
| Bank loans | | 17,497 | 17,536 | – | – |
| Income tax payable | | 623 | 808 | – | – |
| | | 23,987 | 39,734 | 19,402 | 20,437 |
| **NET CURRENT ASSETS/(LIABILITIES)** | | 48,601 | 32,862 | (16,879) | (18,031) |
| **Non-current liabilities** | | | | | |
| Lease liabilities – net of current portion | | 3,039 | 3,336 | 232 | 288 |
| Deferred tax liabilities | | 589 | 501 | 18 | 18 |
| Other non-current liabilities | | 132 | 124 | 103 | 98 |
| | | 3,760 | 3,961 | 353 | 404 |
| **TOTAL LIABILITIES** | | 27,747 | 43,695 | 19,755 | 20,841 |
| **NET ASSETS** | | 102,503 | 102,048 | 37,700 | 36,962 |
| **Equity attributable to equity holders of the Company** | | | | | |
| Share capital | | 27,471 | 27,471 | 27,471 | 27,471 |
| Share premium | | 4,721 | 4,721 | 4,721 | 4,721 |
| Actuarial gains | | 153 | 153 | 116 | 116 |
| Foreign currency translation reserve | | (1,267) | (1,257) | – | – |
| Other reserves | | 394 | 394 | 561 | 561 |
| Revenue reserves | | 72,902 | 72,439 | 7,192 | 6,454 |
| Less: Treasury shares | | (2,361) | (2,361) | (2,361) | (2,361) |
| | | 102,013 | 101,560 | 37,700 | 36,962 |
| **Non-controlling interests** | | 490 | 488 | – | – |
| **Total equity** | | 102,503 | 102,048 | 37,700 | 36,962 |
| **TOTAL EQUITY AND LIABILITIES** | | 130,250 | 145,743 | 57,455 | 57,803 |

Explanatory notes that are material to an understanding of the information:

Note 1 Decrease in Property, Plant and Equipment, net was due to the impact of the deconsolidation of RMKH Glove (Cambodia) Co., Ltd. ("**RMKH Cambodia**") from the Group, after the disposal of its 100% equity interest to Shijiazhuang Hongray Group Co., Ltd. ("**Hongray**"), resulting in derecognition of fixed assets amounting to US$34.2 million, while also recognizing depreciation expenses of US$1.6 million.

Note 2 Increase in Non-trade Receivables amounting to US$26.6 million is also due to the impact of the disposal and deconsolidation of RMKH Cambodia from the Group, resulting in recognition of the receivables from Hongray amounting to US$5.6 million for the remaining consideration of the Disposal Agreement to be collected within FY2026, and outstanding receivables from RMKH Cambodia to the Group amounting to US$21.0 million. This pertains to accumulated advances by the Group to RMKH Cambodia, mostly for financing the construction of the glove factory and working capital requirements in Cambodia. The non-trade receivables are secured with a pledge of RMKH Cambodia's building and six nitrile glove production lines.

Note 3 Decrease in Inventories is primarily due to the impact of the deconsolidation of RMKH Cambodia from the Group, resulting in derecognition of RMKH Cambodia's inventories amounting to US$5.7 million.

Note 4 Decrease in Trade Receivables is primarily due to the impact of the deconsolidation of RMKH Cambodia from the Group, resulting in derecognition of RMKH Cambodia's trade receivable amounting to US$6.1 million.

Note 5 Net increase in Cash and Bank Balances and Fixed Deposits is mainly due to the collection of the partial consideration from Hongray amounting to US$7.5 million for the Disposal Agreement of RMKH Cambodia, net of the working capital requirements of the Group during the period.

Note 6 Decrease in Accounts Payable and Other Current Liabilities is primarily due to the impact of the deconsolidation of RMKH Cambodia from the Group, resulting in derecognition of RMKH Cambodia's accounts payables and other current liabilities amounting to US$15.0 million.

**CONDENSED INTERIM STATEMENTS OF CASH FLOWS**

| | Group US$'000 | |
|---|---|---|
| | Latest Half Year Ended 30 June 2026 | Previous Half Year Ended 30 June 2025 |
| **OPERATING ACTIVITIES** | | |
| Profit before tax | 475 | 243 |
| Adjustments for: | | |
| Depreciation | 1,688 | 1,766 |
| Amortization of: | | |
| Assets held for leasing | 973 | 977 |
| Right-of-use assets | 413 | 365 |
| Intangible assets | 125 | 125 |
| Provision for expected credit losses on non-trade receivables | 1,000 | – |
| Reversal of write-down of inventory | (297) | (1,440) |
| Financial expense | 312 | 308 |
| Other finance costs | 23 | 29 |
| Gain on deconsolidation of subsidiary | (1,045) | – |
| Financial income | (249) | (632) |
| Unrealized foreign exchange losses | 36 | 506 |
| Net changes in pension benefits obligation | 8 | (193) |
| Operating cash flows before working capital changes | 3,462 | 2,054 |
| Change in operating assets: | | |
| Other current assets | (182) | 2,063 |
| Trade receivables | (2,104) | (7,393) |
| Inventories | (1,062) | (1,136) |
| Change in operating liabilities: | | |
| Accounts payable and other current liabilities | (607) | (429) |
| Net cash used in operations | (493) | (4,841) |
| Income taxes paid | (105) | (119) |
| Other finance costs paid | (23) | (29) |
| Net cash used in operating activities | (621) | (4,989) |

| | Group US$'000 | |
|---|---|---|
| | Latest Half Year Ended 30 June 2026 | Previous Half Year Ended 30 June 2025 |
| **INVESTING ACTIVITIES** | | |
| Purchases of: | | |
| Property, plant and equipment | (530) | (1,315) |
| Assets held for leasing | (738) | (1,190) |
| Intangible assets | (114) | – |
| Decrease/(Increase) in: | | |
| Fixed deposits | (6,519) | 786 |
| Right-of-use assets | (1,000) | – |
| Other non-current assets | (129) | (213) |
| Interest received | 249 | 632 |
| Net cash acquired from acquisition of subsidiary | – | 757 |
| Proceeds from sale of subsidiary, net of cash transferred | 6,550 | – |
| Net cash used in investing activities | (2,231) | (543) |
| **FINANCING ACTIVITIES** | | |
| Proceeds from/(Payment of) short-term bank loans – net | 318 | (509) |
| Uplift of fixed deposits | 65 | 2,444 |
| Interest paid | (204) | (211) |
| Payment of lease liabilities | (380) | (322) |
| Net cash (used in)/generated from financing activities | (201) | 1,402 |
| Net decrease in cash and bank balances | (3,053) | (4,130) |
| Cash and bank balances at beginning of period | 15,503 | 16,789 |
| Cash and bank balances at end of period | 12,450 | 12,659 |

**CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY**

**Group**

| | US$'000 | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | Attributed to equity holders of the Group | | | | | | | | | |
| | Share capital | Share premium | Actuarial gains | Translation reserves | Revenue reserves | Other Reserves | Total reserves | Treasury shares | Non-controlling interests | Total equity |
| **Balance at 31 December 2024** | 27,471 | 4,721 | 249 | (1,509) | 77,204 | 394 | 76,089 | (2,361) | 483 | 106,652 |
| Net income for the period | – | – | – | – | 178 | – | 178 | – | 2 | 180 |
| Other comprehensive income (loss) | – | – | (106) | 459 | – | – | 459 | – | – | 353 |
| Total comprehensive income (loss) for the period | – | – | (106) | 459 | 178 | – | 637 | – | 2 | 533 |
| **Balance at 30 June 2025** | 27,471 | 4,721 | 143 | (1,050) | 77,382 | 394 | 76,726 | (2,361) | 485 | 107,185 |
| Net loss for the period | – | – | – | – | (4,943) | – | (4,943) | – | 3 | (4,940) |
| Other comprehensive income (loss) | – | – | 10 | (207) | – | – | (207) | – | – | (197) |
| Total comprehensive income (loss) for the period | – | – | 10 | (207) | (4,943) | – | (5,150) | – | 3 | (5,137) |
| **Balance at 31 December 2025** | 27,471 | 4,721 | 153 | (1,257) | 72,439 | 394 | 71,576 | (2,361) | 488 | 102,048 |
| Net profit for the period | – | – | – | – | 463 | – | 463 | – | 2 | 465 |
| Other comprehensive income (loss) | – | – | – | (10) | – | – | (10) | – | – | (10) |
| Total comprehensive income (loss) for the period | – | – | – | (10) | 463 | – | 453 | – | 2 | 455 |
| **Balance at 30 June 2026** | 27,471 | 4,721 | 153 | (1,267) | 72,902 | 394 | 72,029 | (2,361) | 490 | 102,503 |

**Company**

| | US$'000 | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Share capital | Share premium | Actuarial gains | Revenue reserves | Other reserves | Total reserves | Treasury shares | Total equity |
| **Balance at 31 December 2024** | 27,471 | 4,721 | 112 | 13,475 | 561 | 14,036 | (2,361) | 43,979 |
| Net loss for the period | – | – | – | (98) | – | (98) | – | (98) |
| Other comprehensive loss for the period | – | – | (5) | – | – | – | – | (5) |
| Total comprehensive loss for the period | – | – | (5) | (98) | – | (98) | – | (103) |
| **Balance at 30 June 2025** | 27,471 | 4,721 | 107 | 13,377 | 561 | 13,938 | (2,361) | 43,876 |
| Net loss for the period | – | – | – | (6,923) | – | (6,923) | – | (6,923) |
| Other comprehensive income for the period | – | – | 9 | – | – | – | – | 9 |
| Total comprehensive income (loss) for the period | – | – | 9 | (6,923) | – | (6,923) | – | (6,914) |
| **Balance at 31 December 2025** | 27,471 | 4,721 | 116 | 6,454 | 561 | 7,015 | (2,361) | 36,962 |
| Net profit for the period, representing total comprehensive income for the period | – | – | – | 738 | – | 738 | – | 738 |
| **Balance at 30 June 2026** | 27,471 | 4,721 | 116 | 7,192 | 561 | 7,753 | (2,361) | 37,700 |

## NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS

These notes form an integral part of the condensed interim financial statements.

### 1. CORPORATE INFORMATION

Medtecs International Corporation Limited (the "**Company**") is a limited liability company, which is domiciled in the Philippines, incorporated in Bermuda and is listed on the Catalist board of the Singapore Exchange Securities Trading Limited ("**SGX-ST**").

The Company's registered office is located at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda. The principal place of business of the Company is located at 22/F The World Center Building, #330 Sen. Gil Puyat Avenue Bel-air, Makati City, Philippines.

The principal activities of the Company are manufacturing and selling of medical supplies and equipment and woven and knitted medical textile products and nitrile gloves.

The condensed interim consolidated financial statements have not been audited or reviewed by auditors.

### 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ACCOUNTING ESTIMATES

#### 2.1 Basis of preparation

The condensed interim financial statements of the Company and its subsidiaries (collectively, the "**Group**") have been prepared in accordance with Singapore Financial Reporting Standards (International) (SFRS(I)). The condensed interim financial statements of the Group for the six months ended 30 June 2026 have been prepared in accordance with SFRS(I) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual financial statements for the year ended 31 December 2025.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.2.

The condensed interim financial statements are presented in United States dollars (US$) and all values in the tables are rounded to the nearest thousand ($'000) unless otherwise indicated.

#### 2.2 New and amended standards adopted by the Group

New standards, amendments to standards and interpretations that have been issued at the end of the reporting period but are not yet effective for the half-year ended 30 June 2026 have not been applied in preparing these financial statements. None of these are expected to have a significant effect on the financial statements of the Group and the Company.

#### 2.3 Use of judgments and estimates

In preparing the condensed interim financial statements, management has made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2025.

## 3. SEGMENT AND REVENUE INFORMATION

**Business segments**

The *manufacturing segment* produces and sub-contracts a wide range of medical consumables, including patients' apparels, disposable surgical masks, boot covers and surgical gowns, underpads, adult diapers, blankets, bed linens and medical bandages. These medical consumables are supplied to large multinational corporate medical distributors, group purchasing organisations, pharmaceutical companies and hospital groups in North America and Europe.

The *hospital services segment* provides laundry and leasing services to various hospitals that are outsourcing its non-critical functions.

The *distribution segment* markets Medtecs-branded medical consumables to hospitals, pharmacies and other end users in Asia Pacific and through online channels. The Group also leverages its distribution network to market other branded medical supplies and equipment such as wheelchairs, syringes, and wireless hand-held ultrasounds.

**Geographical segments**

The Group's geographical segments are based on the location of the Group's assets. Sales to external customers disclosed in geographical segments are based on the geographical location of its customers.

### (a) Business segments

The following table presents revenue, results and other information, assets, liabilities and other segment information regarding the Group's business segments for the half-years ended 30 June 2026 and 30 June 2025.

| **Half-Year Ended 30 June 2026** | Manufacturing US$'000 | Hospital services US$'000 | Distribution and others US$'000 | Group US$'000 |
|---|---|---|---|---|
| Revenue | 32,270 | 8,836 | 1,209 | 42,315 |
| Results | (671) | 1,184 | 48 | 561 |
| Financial expenses | | | | (335) |
| Financial income | | | | 249 |
| Income tax expense | | | | (10) |
| Net profit for the period | | | | 465 |
| Total assets | 112,079 | 14,003 | 4,168 | 130,250 |
| Total liabilities | 27,294 | 446 | 7 | 27,747 |
| *Other segment information:* | | | | |
| Capital expenditure | 339 | 191 | – | 530 |
| Depreciation and amortization | 1,856 | 1,288 | 55 | 3,199 |
| Provision for expected credit losses | 1,000 | – | – | 1,000 |
| Reversal of write-down of inventory | (297) | – | – | (297) |
| Gain on deconsolidation of subsidiary | (1,045) | – | – | (1,045) |
| Other non-cash expenses - net | 191 | – | – | 191 |

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (continued)**

**3. SEGMENT AND REVENUE INFORMATION (continued)**

**(a) Business segments (continued)**

| **Half-Year Ended 30 June 2025** | Manufacturing US$'000 | Hospital services US$'000 | Distribution and others US$'000 | Group US$'000 |
|---|---|---|---|---|
| Revenue | 26,611 | 8,598 | 1,229 | 36,438 |
| Results | (1,273) | 1,227 | (6) | (52) |
| Financial expenses | | | | (337) |
| Financial income | | | | 632 |
| Income tax expense | | | | (63) |
| Net profit for the period | | | | 180 |
| Total assets | 121,804 | 14,037 | 4,700 | 140,541 |
| Total liabilities | 33,035 | 317 | 4 | 33,356 |
| *Other segment information:* | | | | |
| Capital expenditure | 112 | 1,203 | – | 1,315 |
| Depreciation and amortization | 1,876 | 1,302 | 55 | 3,233 |
| Reversal of write-down of inventory | (1,440) | – | – | (1,440) |
| Other non-cash expenses - net | 313 | – | – | 313 |

NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (continued)

**3. SEGMENT AND REVENUE INFORMATION (continued)**

**(b) Geographical segments**

Significant revenue and non-current assets information based on the geographical location of customers and assets respectively are as follows:

| | Sales to external customers | | Non-current assets | |
|---|---|---|---|---|
| | 1H2026 | 1H2025 | 1H2026 | FY2025 |
| | US$'000 | US$'000 | US$'000 | US$'000 |
| Singapore | – | – | – | 5 |
| Philippines | 1,559 | 1,591 | 8,245 | 8,760 |
| Cambodia | – | 1,541 | 29,757 | 45,034 |
| Taiwan | 9,083 | 14,300 | 13,522 | 14,126 |
| China | – | – | 985 | 1,023 |
| Bermuda | – | – | 5,153 | 4,199 |
| Luxembourg | 9,903 | 10,666 | – | – |
| United States of America | 15,684 | 5,017 | – | – |
| United Kingdom | 5,462 | 3,124 | – | – |
| Others | 624 | 199 | – | – |
| | 42,315 | 36,438 | 57,662 | 73,147 |

**Disaggregation of revenue**

| | Manufacturing | | Hospital Services | | Distribution and Others | | Total | |
|---|---|---|---|---|---|---|---|---|
| | 1H2026 | 1H2025 | 1H2026 | 1H2025 | 1H2026 | 1H2025 | 1H2026 | 1H2025 |
| | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 | US$'000 |
| **Primary geographical markets** | | | | | | | | |
| North America | 15,818 | 4,366 | – | – | – | – | 15,818 | 4,366 |
| Asia Pacific | 1,071 | 8,045 | 8,836 | 8,598 | 1,209 | 1,229 | 11,116 | 17,872 |
| Europe | 15,365 | 14,179 | – | – | – | – | 15,365 | 14,179 |
| Australia | 16 | 21 | – | – | – | – | 16 | 21 |
| | 32,270 | 26,611 | 8,836 | 8,598 | 1,209 | 1,229 | 42,315 | 36,438 |
| **Timing of transfer of goods or services** | | | | | | | | |
| At a point in time | 32,270 | 26,611 | – | – | 905 | 925 | 33,175 | 27,536 |
| Over time | – | – | 8,836 | 8,598 | 304 | 304 | 9,140 | 8,902 |
| | 32,270 | 26,611 | 8,836 | 8,598 | 1,209 | 1,229 | 42,315 | 36,438 |

**NOTES TO THE CONDENSED INTERIM FINANCIAL STATEMENTS (continued)**

## 4. FINANCIAL INSTRUMENTS

| **As at 30 June 2026**<br>**Group** | Financial assets<br>US$'000 | Financial liabilities<br>US$'000 | Total<br>US$'000 |
|---|---|---|---|
| **Financial assets:** | | | |
| Cash and bank balances and fixed deposits | 22,769 | – | 22,769 |
| Trade receivables | 14,012 | – | 14,012 |
| Non-trade receivables | 26,590 | – | 26,590 |
| Other current assets* | 2,597 | – | 2,597 |
| | 65,968 | – | 65,968 |
| **Financial liabilities:** | | | |
| Bank loans | – | (17,497) | (17,497) |
| Trade payables and other current liabilities** | – | (5,011) | (5,011) |
| Lease liabilities | – | (3,858) | (3,858) |
| | – | (26,366) | (26,366) |
| | 65,968 | (26,366) | 39,602 |

**excluding non-financial assets*

***excluding non-financial liabilities*

| **As at 30 June 2026**<br>**Company** | Financial assets<br>US$'000 | Financial liabilities<br>US$'000 | Total<br>US$'000 |
|---|---|---|---|
| **Financial assets:** | | | |
| Cash and bank balances and fixed deposits | 1,761 | – | 1,761 |
| Trade receivables | 123 | – | 123 |
| Other current assets* | 153 | – | 153 |
| Net investment on sub-lease | 3,874 | – | 3,874 |
| | 5,911 | – | 5,911 |
| **Financial liabilities:** | | | |
| Trade payables and other current liabilities** | – | (656) | (656) |
| Due to subsidiaries (trade) | – | (18,594) | (18,594) |
| Lease liabilities | – | (380) | (380) |
| | – | (19,630) | (19,630) |
| | 5,911 | (19,630) | (13,719) |

**excluding non-financial assets*

***excluding non-financial liabilities*

**4. FINANCIAL INSTRUMENTS (continued)**

| **As at 31 December 2025**<br>**Group** | Financial assets<br>US$'000 | Financial liabilities<br>US$'000 | Total<br>US$'000 |
|---|---|---|---|
| **Financial assets:** | | | |
| Cash and bank balances and fixed deposits | 19,368 | – | 19,368 |
| Trade receivables | 19,252 | – | 19,252 |
| Other current assets* | 2,232 | – | 2,232 |
| | 40,852 | – | 40,852 |
| **Financial liabilities:** | | | |
| Bank loans | – | (17,536) | (17,536) |
| Trade payables and other current liabilities** | – | (10,509) | (10,509) |
| Lease liabilities | – | (4,155) | (4,155) |
| | – | (32,200) | (32,200) |
| | 40,852 | (32,200) | 8,652 |

**excluding non-financial assets*
***excluding non-financial liabilities*

| **As at 31 December 2025**<br>**Company** | Financial assets<br>US$'000 | Financial liabilities<br>US$'000 | Total<br>US$'000 |
|---|---|---|---|
| **Financial assets:** | | | |
| Cash and bank balances and fixed deposits | 1,444 | – | 1,444 |
| Trade receivables | 117 | – | 117 |
| Other current assets* | 158 | – | 158 |
| Net investment on sub-lease | 4,271 | – | 4,271 |
| | 5,990 | – | 5,990 |
| **Financial liabilities:** | | | |
| Trade payables and other current liabilities** | – | (696) | (696) |
| Due to subsidiaries (trade) | – | (19,589) | (19,589) |
| Lease liabilities | – | (436) | (436) |
| | – | (20,721) | (20,721) |
| | 5,990 | (20,721) | (14,731) |

**excluding non-financial assets*
***excluding non-financial liabilities*

## 5. TAXATION

The major components of income tax expense for the half-years ended 30 June 2026 and 30 June 2025 are:

| | Group | | Company | |
|---|---|---|---|---|
| | 1H2026<br>US$'000 | 1H2025<br>US$'000 | 1H2026<br>US$'000 | 1H2025<br>US$'000 |
| Current | 25 | 57 | – | – |
| Deferred income tax:<br>Origination and reversal of temporary differences | (15) | 6 | – | – |
| Income tax expense recognised in the profit and loss accounts | 10 | 63 | – | – |

## 6. DIVIDENDS

No dividends were declared in 1H2026 and FY2025.

## 7. INVESTMENT PROPERTIES

| | Group | |
|---|---|---|
| | 2026<br>US$'000 | 2025<br>US$'000 |
| **Cost:** | | |
| As at 1 January | 5,465 | 5,465 |
| **Accumulated depreciation:** | | |
| As at 1 January | 3,182 | 3,071 |
| Depreciation charge for the period | 55 | 55 |
| As at 30 June | 3,237 | 3,126 |
| Net carrying amount as at 30 June | 2,228 | 2,339 |

The Group's investment properties includes buildings and building improvements that are mainly held to earn rentals and capital appreciation. The Group has no restrictions on the realisability of its investment properties and no contractual obligations to purchase, construct or develop investment property or for repairs, maintenance or enhancements.

## 7. INVESTMENT PROPERTIES (continued)

Investment properties are stated at cost less accumulated depreciation and any accumulated impairment losses. A valuation of the fair value of the investment properties was performed by an independent appraiser. Aggregate fair value of the investment properties was determined using the income approach. Income approach is a method in which the appraiser derives an indication of value for income producing property by converting anticipated future benefits into current property value. The discount rate of 11.1% used under the income approach for valuing anticipated future benefits into current property value is computed under the "Built-Up" method. As at 31 December 2025, fair market value of the investment properties, which is based on its highest and best use, amounted to US$3.5 million. The fair value is categorised under Level 3 (valuation techniques for which the lowest level input that is significant to the fair value measurement is not based on observable data) fair value hierarchy.

## 8. LOANS AND BORROWINGS

Amount repayable in one year or less, or on demand

| As at 30 June 2026 US$'000 | | As at 31 December 2025 US$'000 | |
|---|---|---|---|
| Secured | Unsecured | Secured | Unsecured |
| 15,926 | 1,571 | 15,942 | 1,594 |

### Details of any collateral

Secured short-term bank loans of approximately US$15.9 million as of 30 June 2026 and 31 December 2025, are secured by property, plant and equipment and guarantee deposit, with net book values of approximately US$12.7 million and US$6.4 million as of 30 June 2026 and 31 December 2025, respectively.

## 9. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2026, the Group acquired property, plant and equipment amounting to US$0.5 million (30 June 2025: US$1.3 million).

## 10. SHARE CAPITAL

### 10.1 Share Capital

| | Group and Company |
|---|---|
| | US$'000 |
| **Authorised** | |
| As at 1 January 2025, 31 December 2025 and 30 June 2026 - 1,000,000,000 ordinary shares of US$0.05 each | 50,000 |
| **Issued and paid up** | |
| As at 1 January 2025, 31 December 2025 and 30 June 2026 - 544,911,240 ordinary shares of US$0.05 each | 27,246 |

The Company has only one class of shares: ordinary shares of US$0.05 each, with each share carrying one vote, without restriction. The holders of ordinary shares are entitled to receive dividends as and when declared by the Company and subsequently approved by the shareholders.

### 10.2 Treasury Shares

| | Group and Company |
|---|---|
| | US$'000 |
| As at 1 January 2025, 31 December 2025 and 30 June 2026 - 4,500,000 treasury shares | 2,361 |

There were no changes in the share capital of the Company in the half-year ended 30 June 2026.

The total number of issued Shares (excluding treasury shares) as at 30 June 2026 and 31 December 2025 was 544,911,240. The total number of treasury shares as at 30 June 2026 and 30 June 2025 was 4,500,000, which represented approximately 0.83% of the total number of issued Shares (excluding treasury shares) of 544,911,240 as at 30 June 2026 and 30 June 2025.

The Company had no convertibles or subsidiary holdings as at 30 June 2026 and 30 June 2025.

## 11. SUBSEQUENT EVENTS

There are no known subsequent events which have led to adjustments to this set of interim financial statements.

## OTHER INFORMATION REQUIRED UNDER APPENDIX 7C OF THE SGX-ST LISTING MANUAL SECTION B: RULES OF CATALIST

**1. Whether the same accounting policies and methods of computation as in the issuer's most recently audited annual financial statement have been applied.**

The Group has applied the same accounting policies and methods of computation in the financial statements for the current financial period compared with those of the audited financial statements as at and for the financial year ended 31 December 2025.

**2. If there are any changes in the accounting policies and methods of computation, including any required by an accounting standard, what has changed, as well as the reasons for, and the effect of, the change.**

Not Applicable.

**3. Earnings per ordinary share of the group for the current financial period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends: (a) based on the weighted average number of ordinary shares on issue and (b) on a fully diluted basis (detailing any adjustments made to the earnings).**

| | Group | |
|---|---|---|
| | First Half Ended 30 June 2026 | First Half Ended 30 June 2025 |
| Earnings per ordinary share for the period after deducting any provision for preference dividends: | | |
| (i) Based on weighted average number of ordinary shares in issue during the period | 0.085 US cents | 0.033 US cents |
| (ii) On a fully diluted basis | 0.085 US cents | 0.033 US cents |

Explanatory note to 3 (i) and (ii)

Earnings per share for the six-month periods ended 30 June 2026 and 30 June 2025 are calculated based on the weighted average number of issued ordinary shares, excluding treasury shares, during the six-month periods ended 30 June 2026 and 30 June 2025 of 544,911,240.

**4. Net asset value (for the issuer and group) per ordinary share based on the total number of issued shares excluding treasury shares of the issuer at the end of the: (a) current financial period reported on and (b) immediately preceding financial year.**

| | Group | |
|---|---|---|
| | As at 30 June 2026 | As at 31 December 2025 |
| Net asset value per ordinary share based on the total number of issued shares excluding treasury shares as at the end of the period reported on | 18.72 US cents | 18.64 US cents |

| | Company | |
|---|---|---|
| | As at 30 June 2026 | As at 31 December 2025 |
| Net asset value per ordinary share based on the total number of issued shares excluding treasury shares as at the end of the period reported on | 6.92 US cents | 6.78 US cents |

Explanatory note to 4

The net asset value per ordinary share is calculated based on 544,911,240 issued shares, excluding treasury shares, as at 30 June 2026 and 31 December 2025.

**5. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following: (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

**Business Overview**

The Group's revenue increased by 16.1% from US$36.4 million in 1H2025 to US$42.3 million in 1H2026, mainly driven by higher sales contributions from existing customers of the nitrile glove factory, amounting to US$12.0 million. Excluding the one-off orders from some OEM customers in 1H2025, revenue from the Group's core OEM business remains stable in 1H2026. The Group also leveraged on new hospital contracts and renewals, improving revenue from its hospital services by 2.8%.

**Revenue**

Revenue from the Manufacturing division increased by 21.3% from US$26.6 million in 1H2025 to US$32.3 million in 1H2026 due to higher sales from nitrile gloves.

Revenue from the Hospital Services division increased by 2.8% from US$8.6 million in 1H2025 to US$8.8 million in 1H2026 due to higher linen utilization, contract price increase from renewals and new hospital contracts in Taiwan and Philippines.

Revenue from the Trading and Distribution division slightly decreased by 1.6% from US$1.23 million in 1H2025 to US$1.21 million in 1H2026 arising from lower demand for our healthcare products in Taiwan due to competition.

**Profitability**

The Group's gross profit decreased by 3.8% from US$7.5 million in 1H2025 to US$7.2 million in 1H2026 mainly due to decline in sales from OEM customers and higher operating costs from hospital services. The Group's gross profit margin also decreased from 20.5% in 1H2025 to 17.0% in 1H2026 mainly due to lower-margined nitrile glove sales.

Gross profit from the Manufacturing division slightly decreased by 1.7% from US$5.3 million in 1H2025 to US$5.2 million in 1H2026 due to lower sales from OEM customers.

Gross profit from the Hospital Services division decreased by 9.2% from US$2.0 million in 1H2025 to US$1.8 million in 1H2026 due to increase in laundry costs and write-off of old laundry factory supplies, but mitigated by increase in price from contract renewals and better linen management.

Gross profit from the Trading and Distribution division decreased by 4.4% from US$152,000 in 1H2025 to US$145,000 in 1H2026 due to decline in demand and product offerings in the Taiwan domestic market due to competition.

Other operating income increased significantly by 1,549.1% from US$108,000 in 1H2025 to US$1.8 million in 1H2026 primarily due to gain on deconsolidation of RMKH Cambodia of US$1.0 million, better management of foreign currency exchange exposures and higher scrap sales during the period.

Distribution and selling expenses decreased by 5.3% from US$2.9 million in 1H2025 to US$2.7 million in 1H2026 due to lower freight and advertising costs following lower e-commerce sales. Administrative expenses increased by 19.6% from US$4.8 million in 1H2025 to US$5.7 million in 1H2026 due to general provision for expected credit losses on non-trade receivables of US$1.0 million mainly related to the disposal of RMKH Cambodia.

Financial expenses slightly decreased by 0.6% from US$337,000 in 1H2025 to US$335,000 in 1H2026 due to fewer availments of bank loans. Financial income decreased by 60.6% from US$632,000 in 1H2025 to US$249,000 in 1H2026 due to lower interest income earned from fewer fixed deposit placements made and redemption of bonds in Cambodia last year.

Income tax expenses decreased by 84.1% from US$63,000 in 1H2025 to US$10,000 in 1H2026 due to lower net operating profit in some subsidiaries in 1H2026.

Overall, the Group's net profit after tax increased to US$465,000 in 1H2026 from US$180,000 in 1H2025 mainly due to higher other operating income.

**Cash Flow and Balance Sheet**

The Group's total assets decreased from US$145.7 million as at 31 December 2025 to US$130.3 million as at 30 June 2026 mainly due to the impact of the disposal and deconsolidation of RMKH Cambodia from the Group, resulting in decrease in inventories, trade receivables and property, plant and equipment of US$5.7 million, US$6.1 million and US$34.2 million, respectively. On the other hand, the Group recognized non-trade receivables amounting to US$26.6 million, arising from the Group's receivables from RMKH Cambodia of US$21.0 million and remaining disposal consideration from Hongray of US$5.6 million. Following the disposal of RMKH Cambodia, the Group had higher net cash mainly from the initial proceeds amounting to US$7.5 million, net of working capital requirements of the Group during the period. The Group's total liabilities decreased from US$43.7 million as at 31 December 2025 to US$27.7 million as at 30 June 2026, also mainly due to the disposal and deconsolidation of RMKH Cambodia from the Group, resulting in derecognition of accounts payable and other current liabilities amounting to US$15.0 million.

The Group's cash outflow from operating activities decreased to US$621,000 in 1H2026 from US$5.0 million in 1H2025 due to higher operating income generated and fewer working capital requirements during the period. Cash outflow from investing activities increased to US$2.2 million in 1H2026 from US$543,000 in 1H2025, due to higher fixed deposit placements and new capital expenditures, partially offset by the net proceeds received from the disposal of RMKH Cambodia. Cash outflow from financing activities amounted to US$201,000 in 1H2026 from a cash inflow in 1H2025 of US$1.4 million due to fewer loan availments.

## 6. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

No forecast or prospect statement has been disclosed to shareholders previously.

## 7. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

As we look ahead to the second half of 2026 and the following 12 months, the global operating environment remains uncertain, with ongoing geopolitical tensions, evolving trade policies, inflationary pressures and intense price competition. Against this backdrop, the Group will remain focused on disciplined execution, cash preservation and selective investment in businesses where it has established capabilities. Our priorities are to strengthen the core original equipment manufacturing (OEM) business, expand healthcare services, improve asset and working-capital efficiency, and continue targeted investments in automation, digitalisation and sustainable product development. These initiatives are intended to support revenue resilience, recurring profitability and long-term shareholder value.

**Strengthening the Core OEM Business and Improving Asset Efficiency**

The Group's core OEM business remains resilient, supported by established customer relationships and recurring demand. We will continue to broaden our product and customer pipeline, prioritise strategic, multi-year partnerships over purely transactional engagements, and deepen market penetration in established regions, including the United States, Europe, Taiwan and the Philippines, while selectively pursuing opportunities in high-potential emerging markets.

To compete on value rather than price alone, the Group is refining its product segmentation across entry-level, mid-tier and premium offerings. This strategy will be underpinned by product quality, reliable delivery, regulatory capabilities and technical expertise. We will also continue to expand our portfolio of regulatory-certified and sterilised products, subject to the relevant approvals, and use AI-enabled analytics to improve our understanding of market trends, customer requirements and product customisation opportunities.

Medtecs will continue to improve operational efficiency and cost competitiveness by streamlining manufacturing processes and increasing responsiveness to changing demand. Investments in automation, including automated fabric inspection systems, flatbed cutters and automated pocket stitching machines, have improved production throughput and efficiency. In the coming periods, management will focus on capacity utilisation, production yield, labour productivity, procurement efficiency, product mix and delivery reliability to help offset cost pressures and support margins.

**Expanding Healthcare Services**

Demand for outsourced hospital support services continues to provide growth opportunities. Drawing on the Group's long-standing operations and service capabilities in the Philippines and Taiwan, we will selectively pursue new service contracts and broaden our service offerings, while maintaining service quality, operating discipline and working-capital control.

**Harnessing Technology and Sustainability Initiatives**

To support long-term competitiveness, the Group will continue to advance two strategic pillars through targeted and commercially disciplined investment:

- **Digital Transformation and AI Integration:** We are embedding AI and automation in selected operations to improve precision, productivity and supply chain responsiveness. The Group will continue workforce upskilling, practical AI workshops and implementation of its Artificial Intelligence Usage Policy to support responsible deployment. The objective is to improve production consistency, strengthen decision-making and reduce reliance on manual processes.
- **Sustainability and Product Innovation:** Sustainability remains an important product and operational consideration as customer and regulatory requirements evolve. The Group will continue to develop commercially viable eco-friendly products and packaging, including biodegradable materials for selected PPE accessories and HDPE and paper-based packaging for relevant markets. Stronger supplier partnerships and logistics optimisation will also support supply chain resilience, cost efficiency and business continuity.

**Legal Excellence**

In August 2026, the Group's Legal & Compliance team was shortlisted in the Asian In-House Legal Team of the Year category at The Asia Legal Awards 2026, presented by Law.com International. Our dedicated Legal & Compliance team supports the Group in strategic transactions, governance, compliance and cross-border legal matters, and uses technology to improve the efficiency and consistency of legal operations.

**Strategic Realignment and Capital Discipline**

Under the agreed disposal arrangements, the Group received consideration corresponding to more than 50% of the equity interest in RMKH Cambodia by the end of May 2026 and accordingly deconsolidated RMKH Cambodia with effect from June 2026. Period-on-period revenue comparability may therefore be affected, while the Group's exposure to RMKH Cambodia's operating losses and future capital commitments has been reduced.

Going forward, the management team will remain focused on strengthening the Group's core businesses, exercising tighter cost control, improving operational efficiency, and enhancing the profitability of its product and customer mix. Profitability will continue to be affected by raw material price volatility, price competition, and the timing and cost of investments in technology, automation, and sustainability. The Group will maintain disciplined capital allocation and prioritize the improvement of recurring earnings, operating cash flow, and overall financial resilience.

## 8. If a decision regarding dividend has been made:

***(a) Whether an interim (final) ordinary dividend has been declared (recommended).***

No.

***(b)***

**(i) Amount per share**

Not applicable.

**(ii) Previous corresponding period**

Not applicable.

***(c) Whether the dividend is before tax, net of tax or tax exempt. If before tax or net of tax, state the tax rate and the country where the dividend is derived. (If the dividend is not taxable in the hands of shareholders, this must be stated)***

Not Applicable

***(d) The date the dividend is payable***

Not Applicable

***(e)*** ***The date on which Registrable Transfers received by the company (up to 5.00 pm) will be registered before entitlements to the dividend are determined.***

Not Applicable

**9. If no dividend has been declared (recommended), a statement to that effect and the reason(s) for the decision.**

No dividend has been declared, in order to focus our resources on working capital requirements.

**10. If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.**

The Group does not have a shareholders' mandate for interested person transactions.

**11. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1).**

The Company hereby confirms that it has procured undertakings from all its directors and executive officers (in the format as set out in Appendix 7H) in accordance with Rule 720(1) of the Catalist Rules.

**12. Disclosures on Incorporation, Acquisition and Realisation of Shares pursuant to Rule 706A**

On 10 April 2026, the Group entered into a Disposal Agreement with Shijiazhuang Hongray Group Co., Ltd. for the proposed disposal of its entire equity interest in RMKH Glove (Cambodia) Co., Ltd. ("RMKH Cambodia") for a consideration of approximately US$13.1 million ("Consideration"), subject to adjustment in accordance with the terms of the Disposal Agreement. The Consideration was arrived at after arm's length negotiations on a willing-buyer willing-seller basis, taking into account, inter alia, the net asset value of RMKH Cambodia of approximately US$11.5 million. An initial cash instalment of US$ 5.0 million (representing approximately 38% of the Consideration) is payable upon the initial completion of the disposal (the "Initial Closing") and the remaining 62% of the Consideration is payable in cash instalments over a period of not more than 12 months following the Initial Closing.

Please refer to the Company's announcement dated 10 April 2026 for more information.

**ON BEHALF OF THE BOARD**

Clement Yang Ker-Cheng
Chairman
Date: 14 August 2026

**MEDTECS INTERNATIONAL CORPORATION LIMITED**
(Incorporated in Bermuda)

**CONFIRMATION BY THE BOARD OF DIRECTORS
PURSUANT TO RULE 705(5) OF THE
LISTING MANUAL SECTION B: RULES OF CATALIST**

We, Clement Yang Ker-Cheng and William Yang Weiyuan, being two of the Directors of Medtecs International Corporation Limited (the "Company"), do hereby confirm on behalf of the Directors of the Company, that, to the best of our knowledge, nothing has come to the attention of the Board of Directors of the Company which may render the unaudited interim financial statements of the Company and of the Group for the half year ended 30 June 2026 to be false or misleading in any material aspect.

For and on behalf of the Board
of MEDTECS INTERNATIONAL CORPORATION LIMITED

| | |
|---|---|
| Name: Clement Yang Ker-Cheng | Name: William Yang Weiyuan |
| Director | Director |

Date: 14 August 2026